Provided herein is a method of detecting the presence or absence of Serine Protease Inhibitor Kazal-type 1 (SPINK1) in a subject, comprising obtaining a biological sample comprising genomic DNA from a subject having or suspected of having chronic and acute lung diseases, and detecting the presence or absence of the SPINK1 in the biological sample.

Disclosed are methods for assessing the severity of a coronavirus infection through the measurement of caspase 4 and methods of treating a coronavirus infection comprising administering to an infected subject an inhibitor of CASP4 or its downstream effectors IL-1 B, Cxcl1, or Willebrand factor (vWF). The coronaviral infection may be a SARS-CoV-2 variant.

Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.

The present invention relates to a method for diagnosing a lung disease based on antibodies against microorganism-derived vesicles and, more particularly, to a method for diagnosing a lung disease by performing bacterial metagenome analysis using samples derived from a subject to analyze an increase or decrease in IgG, IgG1 and/or IgG4 levels in extracellular vesicles derived from specific bacteria.

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

The invention related to a method for selective enrichment of glycoproteins from a sample comprising proteins, the method comprising: determining the concentration of proteins in the sample or providing the sample with a defined concentration of proteins; incubating particles in the sample to form a protein corona comprising glycoproteins bound to the surface of the particles, wherein the protein concentration to the total surface area of the particles is selected, and/or the particle material is selected, in order to enrich for a specific glycoprotein species on the protein corona; and optionally isolating the protein corona from the sample; and associated methods of screening for biomarkers and diagnosis, and associated compositions.

Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.